cdk 4/6 inhibitors for patients with recurrent er /her2- breast cancer: 2023 best of breast
Published 1 year ago • 368 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
26:08
metastatic hormone positive breast cancer | 2023 ku breast cancer year in review conference
-
0:37
cdk4/6 inhibitors in her2-negative breast cancer based on phase iii monaleesa-7 trial
-
1:20
dr. finn on new cdk 4/6 inhibitors for breast cancer
-
4:39
treatment following relapse on cdk4/6 inhibitors
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
23:44
park and graff explore the evolving role of cdk4/6 inhibitors in metastatic breast cancer
-
2:24
differentiating factors of abemaciclib among the cdk 4/6 inhibitors for breast cancer
-
0:57
evaluating the benefits of selective cdk4 inhibition in hr /her2- breast cancer
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
3:21
benefits and challenges of cdk4/6 inhibitors
-
1:47
dr. tripathy on combination strategies with cdk4/6 inhibitors in breast cancer
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
5:34
considerations for treating patients with cdk4/6 inhibitors
-
3:05
an overview of cdk 4/6 inhibitors for first line er advanced breast cancer
-
1:11
dr. accordino on the utility of cdk4/6 inhibitors in hr /her2– breast cancer